Results from a Phase 1/2 trial of BB2603, a terbinafine‐based topical nano‐formulation, in onychomycosis and tinea pedis.
Saved in:
| Title: | Results from a Phase 1/2 trial of BB2603, a terbinafine‐based topical nano‐formulation, in onychomycosis and tinea pedis. |
|---|---|
| Authors: | Fuhr, Rainard1 (AUTHOR), Cook, David2 (AUTHOR), Ridden, John2 (AUTHOR), Nield, Kerry2 (AUTHOR), Leigh, Emma2 (AUTHOR) emma.leigh@blueberrytherapeutics.com, Cook, Julie2 (AUTHOR), Davies‐Strickleton, Heather2 (AUTHOR), Dobmeyer, Juergen2 (AUTHOR) |
| Source: | Mycoses. Jun2022, Vol. 65 Issue 6, p661-669. 9p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
